TriSalus FY25 Revenue Expected at $45.2M
Reports preliminary FY25 revenue $45.2M, consensus $44.62M. "TriSalus continued to deliver strong commercial performance in the fourth quarter and exceeded our 2025 guidance of 50% annual revenue growth, underscoring the meaningful clinical adoption of our TriNav product suite and proprietary PEDD platform across a broad range of solid tumor indications," said Mary Szela, president and CEO of TriSalus. "We are pleased not only with our commercial execution but also with the sustained progress on our strategic initiatives, including expansion of the TriNav platform across multiple indications beyond the liver and deepening our engagement within the interventional radiology community. Looking ahead to 2026, we expect full-year revenues to be in a range of approximately $60 million to $62 million."
Trade with 70% Backtested Accuracy
Analyst Views on TLSI
About TLSI
About the author
TriSalus Board Changes and New Appointment
- Board Member Change: TriSalus announced the resignation of Dr. Arjun Desai from the Board, expressing gratitude for his contributions during a critical development phase, highlighting the company's commitment to leadership stability.
- New Board Appointment: Michael P. Stansky has been appointed as a new board member effective February 4, 2026, bringing 40 years of experience in healthcare investment, which may provide new strategic insights and resources for the company.
- Investment Management Expertise: Stansky previously served as Managing Director at Tudor Investment Corporation, overseeing long/short equity investments, and his extensive investment management background is expected to enhance TriSalus's performance in capital markets and value creation.
- Platform Potential Recognition: Stansky acknowledged the potential of TriSalus's PEDD™ platform to significantly improve treatment outcomes for patients with solid tumors, indicating the company's strategic focus on innovative drug delivery technologies.
TriSalus Life Sciences Announces Publication of Safety and Efficacy Results for a Novel Pressure-Enabled Thyroid Embolization Technique
New Treatment Evaluation: TriSalus Life Sciences has published clinical data on its Pressure-Enabled Drug Delivery (PEDD) technology for thyroid parenchymal embolization, showing it as a safe and effective option for patients with symptomatic thyroid disease, achieving 100% technical and clinical success in a study of 22 patients.
Future Research Initiatives: A multi-institutional registry study called PROTECT is underway to further validate these findings and explore the broader applicability of pressure-enabled embolization techniques in treating benign thyroid conditions.
TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock
TriSalus Life Sciences Exchange Offer: TriSalus Life Sciences has completed its exchange offer for Preferred Stock, allowing shareholders to convert their shares into common stock at a rate of 3.3 shares per preferred share, with approximately 98.82% of outstanding preferred shares tendered.
Amendment Approval and Future Plans: Due to sufficient shareholder agreement, the company will amend the terms of the Preferred Stock, resulting in remaining shares converting to common stock at a slightly lower rate, while continuing to focus on innovative drug delivery technologies for cancer treatment.
TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital Structure
Exchange Offer Announcement: TriSalus Life Sciences has initiated an exchange offer for its Series A Convertible Preferred Stock, allowing shareholders to convert their preferred shares into common stock to simplify the company's capital structure and enhance transparency.
Consent Solicitation Details: The company is also seeking approval from preferred shareholders for an amendment that would enable automatic conversion of remaining preferred shares into common stock at a reduced exchange ratio, with a deadline for participation set for July 23, 2025.
TriSalus Launches TriNav FLX To Enhance Drug Delivery In Complex Peripheral Vessels
New Product Launch: TriSalus Life Sciences has introduced the TriNav FLX Infusion System, enhancing trackability and flexibility for Interventional Radiologists in treating solid tumors while retaining the benefits of Pressure-Enabled Drug Delivery (PEDD).
Key Features and Impact: The system offers improved navigation through complex vascular structures with a 28% reduction in required navigation force, and it is reimbursable under specific HCPCS codes, supporting procedural planning and therapy delivery.
TriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. Patience
CFO Appointment: David Patience has been appointed as the new Chief Financial Officer of TriSalus Life Sciences, effective July 1, 2025, succeeding James E. Young who stepped down for personal reasons. Dan Giordano will serve as acting CFO during the transition.
Company Overview: TriSalus Life Sciences focuses on oncology and aims to improve treatment outcomes for patients with solid tumors through innovative drug delivery technologies and investigational immunotherapies, including their proprietary Pressure-Enabled Drug Delivery™ approach.
TriSalus Board Changes and New Appointment
- Board Member Change: TriSalus announced the resignation of Dr. Arjun Desai from the Board, expressing gratitude for his contributions during a critical development phase, highlighting the company's commitment to leadership stability.
- New Board Appointment: Michael P. Stansky has been appointed as a new board member effective February 4, 2026, bringing 40 years of experience in healthcare investment, which may provide new strategic insights and resources for the company.
- Investment Management Expertise: Stansky previously served as Managing Director at Tudor Investment Corporation, overseeing long/short equity investments, and his extensive investment management background is expected to enhance TriSalus's performance in capital markets and value creation.
- Platform Potential Recognition: Stansky acknowledged the potential of TriSalus's PEDD™ platform to significantly improve treatment outcomes for patients with solid tumors, indicating the company's strategic focus on innovative drug delivery technologies.
TriSalus Life Sciences Announces Publication of Safety and Efficacy Results for a Novel Pressure-Enabled Thyroid Embolization Technique
New Treatment Evaluation: TriSalus Life Sciences has published clinical data on its Pressure-Enabled Drug Delivery (PEDD) technology for thyroid parenchymal embolization, showing it as a safe and effective option for patients with symptomatic thyroid disease, achieving 100% technical and clinical success in a study of 22 patients.
Future Research Initiatives: A multi-institutional registry study called PROTECT is underway to further validate these findings and explore the broader applicability of pressure-enabled embolization techniques in treating benign thyroid conditions.
TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock
TriSalus Life Sciences Exchange Offer: TriSalus Life Sciences has completed its exchange offer for Preferred Stock, allowing shareholders to convert their shares into common stock at a rate of 3.3 shares per preferred share, with approximately 98.82% of outstanding preferred shares tendered.
Amendment Approval and Future Plans: Due to sufficient shareholder agreement, the company will amend the terms of the Preferred Stock, resulting in remaining shares converting to common stock at a slightly lower rate, while continuing to focus on innovative drug delivery technologies for cancer treatment.
TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital Structure
Exchange Offer Announcement: TriSalus Life Sciences has initiated an exchange offer for its Series A Convertible Preferred Stock, allowing shareholders to convert their preferred shares into common stock to simplify the company's capital structure and enhance transparency.
Consent Solicitation Details: The company is also seeking approval from preferred shareholders for an amendment that would enable automatic conversion of remaining preferred shares into common stock at a reduced exchange ratio, with a deadline for participation set for July 23, 2025.
TriSalus Launches TriNav FLX To Enhance Drug Delivery In Complex Peripheral Vessels
New Product Launch: TriSalus Life Sciences has introduced the TriNav FLX Infusion System, enhancing trackability and flexibility for Interventional Radiologists in treating solid tumors while retaining the benefits of Pressure-Enabled Drug Delivery (PEDD).
Key Features and Impact: The system offers improved navigation through complex vascular structures with a 28% reduction in required navigation force, and it is reimbursable under specific HCPCS codes, supporting procedural planning and therapy delivery.
TriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. Patience
CFO Appointment: David Patience has been appointed as the new Chief Financial Officer of TriSalus Life Sciences, effective July 1, 2025, succeeding James E. Young who stepped down for personal reasons. Dan Giordano will serve as acting CFO during the transition.
Company Overview: TriSalus Life Sciences focuses on oncology and aims to improve treatment outcomes for patients with solid tumors through innovative drug delivery technologies and investigational immunotherapies, including their proprietary Pressure-Enabled Drug Delivery™ approach.
